Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,856 | 2 | 70.7% |
| Food and Beverage | $2,211 | 25 | 26.7% |
| Education | $214.97 | 3 | 2.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $6,827 | 12 | $0 (2024) |
| Seagen Inc. | $582.92 | 5 | $0 (2023) |
| Daiichi Sankyo Inc. | $187.49 | 1 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $162.47 | 2 | $0 (2023) |
| PFIZER INC. | $132.71 | 2 | $0 (2024) |
| Genentech USA, Inc. | $116.91 | 2 | $0 (2023) |
| Janssen Research & Development, LLC | $102.48 | 1 | $0 (2024) |
| Celgene Corporation | $81.12 | 3 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $63.34 | 1 | $0 (2024) |
| Amgen Inc. | $26.05 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,834 | 9 | GENZYME CORPORATION ($1,536) |
| 2023 | $6,279 | 19 | GENZYME CORPORATION ($5,247) |
| 2022 | $43.93 | 1 | GENZYME CORPORATION ($43.93) |
| 2021 | $125.00 | 1 | Seagen Inc. ($125.00) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $82.72 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $118.68 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Janssen Scientific Affairs, LLC | TALVEY (Biological) | Food and Beverage | In-kind items and services | $63.34 | General |
| Category: Oncology | ||||||
| 05/23/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,092.00 | General |
| 05/13/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $118.17 | General |
| Category: Oncology | ||||||
| 04/29/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $106.11 | General |
| Category: Oncology | ||||||
| 03/20/2024 | PFIZER INC. | — | Education | In-kind items and services | $49.99 | General |
| 03/15/2024 | Janssen Research & Development, LLC | TALVEY (Biological) | Food and Beverage | In-kind items and services | $102.48 | General |
| Category: Oncology | ||||||
| 01/24/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $100.78 | General |
| Category: Oncology | ||||||
| 12/10/2023 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $99.79 | General |
| 12/08/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $4,764.00 | General |
| Category: Oncology | ||||||
| 12/08/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $69.99 | General |
| Category: Oncology | ||||||
| 12/08/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: Oncology | ||||||
| 11/21/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $187.49 | General |
| 10/18/2023 | Seagen Inc. | — | Education | In-kind items and services | $99.99 | General |
| 10/12/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology | ||||||
| 09/27/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $82.45 | General |
| Category: Oncology | ||||||
| 08/01/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $142.94 | General |
| Category: Oncology | ||||||
| 07/20/2023 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $124.36 | General |
| 07/20/2023 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $38.11 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $22.09 | General |
| Category: Hematology | ||||||
| 06/07/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $29.42 | General |
| Category: Hematology | ||||||
| 05/30/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $136.51 | General |
| 05/17/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $29.61 | General |
| Category: Hematology | ||||||
| 03/29/2023 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: BioOncology | ||||||
About Dr. Tarek Mouhieddine, MD
Dr. Tarek Mouhieddine, MD is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/19/2019. The National Provider Identifier (NPI) number assigned to this provider is 1831658731.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tarek Mouhieddine, MD has received a total of $8,282 in payments from pharmaceutical and medical device companies, with $1,834 received in 2024. These payments were reported across 30 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($5,856).
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 03/19/2019
- Last Updated 10/12/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1831658731
Products in Payments
- SARCLISA (Biological) $5,554
- ADCETRIS (Biological) $417.94
- TALVEY (Biological) $165.82
- ELREXFIO (Drug) $82.72
- Pomalyst (Drug) $81.12
- REZUROCK (Drug) $38.11
- Blincyto (Biological) $26.05
- Venclexta (Biological) $17.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795